Little Aziyo is growing a new regenerative med company, led by some familiar faces in the biz
A few days ago, the small regenerative medicine company Aziyo Biologics reported to the SEC that it had raised $12 million, just as it was in the process of buying out a small, Georgia-based company called CorMatrix Cardiovascular.
The deal put together some very familiar faces in the regenerative medicine world with close ties to Osiris Therapeutics, one of the pioneers in regenerative medicine which has been struggling to restate several years of earnings — a struggle that spurred Nasdaq recently to kick the stock over to the Pink Sheets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
